In general, sialyllactose-conjugated dendrimers represent an attractive option for the development of novel antivirals for influenza as they mainly target HA, thereby enabling their combined application with drugs targeting NA in order to maximize efficiency and reduce the emergence of antiviral drug resistance. Here, XK is linked to influenza.